CA2597193A1 - Composes et utilisations - Google Patents

Composes et utilisations Download PDF

Info

Publication number
CA2597193A1
CA2597193A1 CA002597193A CA2597193A CA2597193A1 CA 2597193 A1 CA2597193 A1 CA 2597193A1 CA 002597193 A CA002597193 A CA 002597193A CA 2597193 A CA2597193 A CA 2597193A CA 2597193 A1 CA2597193 A1 CA 2597193A1
Authority
CA
Canada
Prior art keywords
alkyl
halo
groups
substituents selected
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002597193A
Other languages
English (en)
Inventor
Sachin Govindrao Mahale
Bhabatosh Chaudhuri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
De Montfort University
Original Assignee
De Montfort University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by De Montfort University filed Critical De Montfort University
Priority to CA002597193A priority Critical patent/CA2597193A1/fr
Publication of CA2597193A1 publication Critical patent/CA2597193A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002597193A 2007-08-13 2007-08-13 Composes et utilisations Abandoned CA2597193A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002597193A CA2597193A1 (fr) 2007-08-13 2007-08-13 Composes et utilisations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002597193A CA2597193A1 (fr) 2007-08-13 2007-08-13 Composes et utilisations

Publications (1)

Publication Number Publication Date
CA2597193A1 true CA2597193A1 (fr) 2009-02-13

Family

ID=40348357

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002597193A Abandoned CA2597193A1 (fr) 2007-08-13 2007-08-13 Composes et utilisations

Country Status (1)

Country Link
CA (1) CA2597193A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013071415A1 (fr) * 2011-11-15 2013-05-23 University Health Network Ciblage de la voie de rb destiné à la prévention du cancer
WO2013078544A1 (fr) * 2011-11-29 2013-06-06 Beta Pharma Canada Inc. Composés du type amides hétérocycliques inhibiteurs de la hdac 6 et utilisés comme agents anti-tumoraux
US8618299B2 (en) 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
US8629158B2 (en) 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8637501B2 (en) 2009-07-01 2014-01-28 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
US8716308B2 (en) 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
CN113332282A (zh) * 2021-06-16 2021-09-03 南方海洋科学与工程广东省实验室(湛江) 一种Fascaplysin类化合物的应用

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9650378B2 (en) 2008-01-11 2017-05-16 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
US8716308B2 (en) 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
US9296743B2 (en) 2008-01-11 2016-03-29 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8618299B2 (en) 2009-07-01 2013-12-31 Albany Molecular Research, Inc. Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof
US8629158B2 (en) 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8637501B2 (en) 2009-07-01 2014-01-28 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
WO2013071415A1 (fr) * 2011-11-15 2013-05-23 University Health Network Ciblage de la voie de rb destiné à la prévention du cancer
JP2014533734A (ja) * 2011-11-29 2014-12-15 ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． Ｈｄａｃ６阻害剤・抗腫瘍剤用複素環アミド化合物
CN103974956A (zh) * 2011-11-29 2014-08-06 南京奥昭生物科技有限公司 作为hdac6抑制剂和用作抗肿瘤剂的杂环酰胺化合物
US9345905B2 (en) 2011-11-29 2016-05-24 Nanjing Allgen Pharma Co. Ltd. Heterocyclic amides compounds which are HDAC6 inhibitors and used as anti-tumoral agents
CN103974956B (zh) * 2011-11-29 2016-07-06 南京奥昭生物科技有限公司 作为hdac6抑制剂和用作抗肿瘤剂的杂环酰胺化合物
WO2013078544A1 (fr) * 2011-11-29 2013-06-06 Beta Pharma Canada Inc. Composés du type amides hétérocycliques inhibiteurs de la hdac 6 et utilisés comme agents anti-tumoraux
CN113332282A (zh) * 2021-06-16 2021-09-03 南方海洋科学与工程广东省实验室(湛江) 一种Fascaplysin类化合物的应用

Similar Documents

Publication Publication Date Title
WO2009022104A1 (fr) Dérivés de fascaplysine et leur utilisation dans le traitement d'un cancer
CA2597193A1 (fr) Composes et utilisations
US20220315566A1 (en) Methods of treating cancer
Frolova et al. Exploring natural product chemistry and biology with multicomponent reactions. 5. Discovery of a novel tubulin-targeting scaffold derived from the rigidin family of marine alkaloids
JP6165748B2 (ja) 脱ユビキチン活性の阻害方法
JP2016532668A (ja) 非ホジキンリンパ腫を治療するための、ｈｄａｃ阻害剤単独またはｐｉ３ｋ阻害剤との組み合わせ
Ugwu et al. Synthesis and structural activity relationship study of antitubercular carboxamides
Partridge et al. 2, 4-Diaminothieno [3, 2-d] pyrimidines, a new class of anthelmintic with activity against adult and egg stages of whipworm
Wróbel et al. Synthesis and biological evaluation of new multi-target 3-(1H-indol-3-yl) pyrrolidine-2, 5-dione derivatives with potential antidepressant effect
Fu et al. Discovery of novel indole derivatives that inhibit NEDDylation and MAPK pathways against gastric cancer MGC803 cells
Lamut et al. Anti-influenza virus activity of benzo [d] thiazoles that target heat shock protein 90
EP3177621B1 (fr) Nouveaux inhibiteurs de hdac6 et leurs utilisations
US20090312324A1 (en) Compositions and Methods Related to RAD51 Inactivation in the Treatment of Neoplastic Diseases, and Especially CML
JP4740152B2 (ja) 末梢性５−ｈｔ受容体の修飾因子
Pojarová et al. [(2-Phenylindol-3-yl) methylene] propanedinitriles inhibit the growth of breast cancer cells by cell cycle arrest in G2/M phase and apoptosis
Voura et al. Synthesis, structural modification, and bioactivity evaluation of substituted acridones as potent microtubule affinity-regulating kinase 4 inhibitors
US9261497B2 (en) Method of treating cancer with modulators of SCFSkp2
Barasa et al. Synthesis and biological evaluation of structurally diverse benzimidazole scaffolds as potential chemotherapeutic agents
JP2020526495A (ja) ヘテロクロマチン遺伝子抑制阻害薬
KR102053933B1 (ko) Trap1 저해제로서 유용한 화합물 및 이를 포함하는 항암용 조성물
JPWO2021168313A5 (fr)
KR20230067637A (ko) 근이영양증을 치료하기 위한 조성물 및 방법
Kumar et al. Synthesis, characterization and biological investigations of some new Oxadiazoles: In-vitro and In-Silico approach
Bosco Exploring DHX30, an RNA helicase that coordinates cytoplasmic translation and mitochondrial function contributing to cancer cell survival
WO2023107880A1 (fr) Inhibiteurs de la mitofusine et leurs utilisations

Legal Events

Date Code Title Description
FZDE Dead